Biotechnology
CVS results top expectations, lifted by strong health services revenue
A woman walks past a CVS Pharmacy in Washington, D.C., on Nov. 2, 2022. Brendan Smialowski | AFP | Getty Images CVS on Wednesday reported third-quarter adjusted earnings and revenue that topped Wall Street’s expectations, lifted in part by strong revenue from the company’s health services business. CVS booked sales of $89.76 billion for the […]
Read More
Pfizer swings to quarterly loss due to Paxlovid, Covid vaccine write-offs
CFOTO | Future Publishing | Getty Images Pfizer on Tuesday reported a narrower than expected loss for the third quarter as the drugmaker recorded charges largely related to struggles for its Covid antiviral treatment Paxlovid and Covid vaccine. Pfizer said that it recorded a $5.6 billion charge for inventory write-offs in the third quarter due […]
Read More
Some pharmacy staff from Walgreens, other chains are walking out again — here’s what you need to know
A sign advertises COVID-19 (coronavirus) vaccine shots at a Walgreens Pharmacy in Somerville, Massachusetts, August 14, 2023. Brian Snyder | Reuters Some pharmacy staff from Walgreens and other drugstore chains are planning to walk out next week in the latest pushback against what they call unsafe working conditions that put both employees and patients at […]
Read More
Pharmacy staff from Walgreens, CVS say they’re at a breaking point — here’s what their days look like
Signs offering COVID-19 vaccinations are seen outside of a CVS pharmacy in Washington, DC. Mandel Ngan | AFP | Getty Images Many pharmacy employees at some of the largest U.S. drugstore chains say they’re reaching a breaking point. On top of verifying, filling and dispensing prescriptions, pharmacists and support staff are responsible for administering vaccines, […]
Read More
Pfizer’s combination Covid, flu vaccine will move to final-stage trial after positive data
CFOTO | Future Publishing | Getty Images Pfizer on Thursday said its combination vaccine candidates targeting Covid and the flu will move to a final-stage trial in the coming months after showing positive initial results in an early to mid-stage study. That moves the pharmaceutical giant and its German partner BioNTech one step closer to […]
Read More
Bristol Myers Squibb earnings top estimates even as top-selling drug fights generic competition
Bristol Myers Squibb on Thursday reported quarterly adjusted earnings that topped expectations and posted revenue in line with estimates, even as sales of the company’s popular blood cancer drug Revlimid plummeted due to generic competition. Bristol Myers, one of the world’s largest pharmaceutical companies, raked in $10.96 billion in revenue for the third quarter, down […]
Read More
Merck results beat expectations on strong Keytruda sales, surprise Covid drug growth
Merck headquarters in Rahway, New Jersey, on Tuesday, April 18, 2023. Christopher Occhicone | Bloomberg | Getty Images Merck on Thursday reported third-quarter revenue and adjusted earnings that topped expectations on strong sales of its blockbuster cancer drug Keytruda, HPV vaccine Gardasil and surprisingly, its Covid drug Lagevrio. The pharmaceutical giant also increased its full-year […]
Read More
More convenient form of breakthrough Alzheimer’s drug Leqembi shows promising results in study
Eisai on Wednesday said an injectable version of the Alzheimer’s drug Leqembi showed promising initial results in a clinical trial, potentially paving the way for a new and more convenient option for administering the antibody treatment. However, the injection did not cause lower rates of brain swelling and bleeding, which are Leqembi’s most concerning side […]
Read More
Mike Johnson elected Residence speaker, placing Louisiana Republican in the highlight
Republican Rep. Mike Johnson of Louisiana was elected speaker of the Dwelling of Associates on Wednesday, ending a 3-week management crisis that has paralyzed Congress. Vice chairman of the Home Republican meeting and a tough-proper conservative, Johnson had maintained a lower community profile right until he was thrust into the spotlight this week immediately after […]
Read More
RSV vaccine from GSK shows potential to protect adults 50 to 59
A vaccine from GlaxoSmithKline showed the potential to protect adults ages 50 to 59 from respiratory syncytial virus in a late-stage clinical trial, the company said Wednesday. The initial trial results suggest that GSK’s shot, known as Arexvy, could help protect a wider population from RSV, a disease that causes thousands of hospitalizations and deaths […]
Read More